Trial Profile

Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir/ritonavir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
Indications HIV-2 infections
Focus Therapeutic Use
Acronyms RESIST-2

18 Dec 2021 Results published in the Trials
20 Jan 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:COVID-19 and Funding.
17 Jan 2020 Planned primary completion date changed from 1 Jan 2022 to 31 May 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com